Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 10/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.52 |
| ▸ | HTR3B | O95264 | 5/20 | 0.52 |
| ▸ | HTR3A | P46098 | 5/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4574565 | 0.98 | ADRB1 (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3038730 | 0.80 | CHKA (0.43) | TP53CYP1A2THRBCYP2C19HTT | |
| SCHEMBL13118688 | 0.80 | ADRB1 (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1068578 | 0.78 | ALDH1A1 (0.43) | TP53THRBHTTKDM4EALDH1A1 | |
| SCHEMBL1267527 | 0.77 | HRH4 (0.35) | CHRM2CHRM4CHRM1CHRM3HTR1A | |
| SCHEMBL27743819 | 0.75 | LMNA (0.52) | TP53CYP1A2HTTKDM4EALDH1A1 | |
| SCHEMBL3442708 | 0.75 | HTR7 (0.67) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5570604 | 0.74 | ADRB1 (0.77) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL4575189 | 0.73 | MAPT (0.43) | HTR2CALDH1A1LMNA | |
| SCHEMBL6354195 | 0.72 | CYP2A6 (0.56) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580229-B | Preparation method of bripiprazole | 湖南一格制药有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-113979915-B | Dopamine D 2 Receptor dual ligand compounds and uses | 常州大学 | 2023-07-25 | — | — | CN | disclosed |
| EP-4143163-A1 | ANTAGONISTS OF GPR39 PROTEIN | Oregon Health & Science University (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-113979915-A | Dopamine D2Receptor dibit ligand type compound and application | 常州大学 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020042903-A1 | SALT OF CYCLOHEXANE DERIVATIVE | 浙江京新药业股份有限公司 | 2020-03-05 | — | — | WO | disclosed |
| CN-104011054-B | As the thieno of potassium channel inhibitors and Furanopyrimidines class and pyridines | 森申有限公司 | 2016-08-24 | — | — | CN | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2515656-B1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-08-06 | — | — | EP | disclosed |
| EP-2515656-B1 | AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2014-08-06 | — | — | EP | disclosed |
| US-5380840-A | Treating spinal trauma, head injury, subarachnoid hemorrhage; reduced side effects | THE UPJOHN COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| US-5322943-A | As substituents on steroids are useful as pharmaceutical agents for treating a number of conditions | THE UPJOHN COMPANY (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0587048-A2 | Heteroarenylpiperazines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5272148-A | Heteroarenylpiperazines | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-12-21 | — | — | US | disclosed |
| US-5268477-A | Containing a pyrrolidine or pyridine ring structure | THE UPJOHN COMPANY (US) | 1993-12-07 | — | — | US | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-5175281-A | Antiulcer, antiinflammatory, antiischemic, antiallergen, antisecretory, wound healing agents; cardiovascular disorders | THE UPJOHN COMPANY (US) | 1992-12-29 | — | — | US | disclosed |
| US-5099019-A | Central nervous system steroid derivative drugs | UPJOHN COMPANY (US) | 1992-03-24 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | ADRB1 1401/4885HTR3E 2503/4885HTR3B 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.